Author:
Aref Salah,Khaled Omnyia,Menshawy Nadia El,Azmy Emad,Aref Mohamed,Salama Osama,Khaled Nada
Abstract
Abstract
Objective
This study aimed to address the prognostic impact of SOX2 and OCT3/4 expression on adult acute leukemia patients’ outcomes.
Methods
SOX2 and OCT3/4 expression by blast cells were evaluated by flow cytometry in 80 acute leukemia patients and 8 healthy controls.
Results
Baseline SOX2 and OCT3/4 expression were significantly higher in both ALL (P = < 0.001, P = 0.005 respectively) and AML patients (P < 0.001, P = 0.003 respectively) as compared to control, and decline at complete remission (CR) and elevated again at relapse. High SOX2 and OCT3/4 levels were significantly correlated with the presence of adverse risk stratification parameters.
Conclusion
Our findings indicated that both SOX2 and OCT3/4 could serve as biomarkers that could improve risk stratification of acute leukemia patients. Also, both SOX2 and OCT3/4 might be a therapeutic target, especially in resistant acute leukemia.
Publisher
Springer Science and Business Media LLC
Reference34 articles.
1. Sas, V., Moisoiu, V., Teodorescu, P., et al. Approach to the adult acute lymphoblastic leukemia patient. J Clin Med.2019; 8(8). https://doi.org/10.3390/jcm8081175.
2. Siegel, Rebecca L., Miller, Kimberly D., Fuchs, Hannah E., et al. Cancer statistics, 2022. CA Cancer J Clin. 72(1), 7-33. https://doi.org/10.3322/caac.21708.
3. National Cancer Institute. Cancer stat facts: leukemia-acute myeloid leukemia. U.S. Department of Health and Human Services, National Institutes of Health. 2021; https://seer.cancer.gov/statfacts/html/amyl.html.
4. Howlader N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2014, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2014/ , based on November 2016 SEER data submission, posted to the SEER web site, April 2017.
5. Malard Florent. Mohty, Mohamad. Acute lymphoblastic leukaemia. Lancet. 2020;395(10230):1146–62. https://doi.org/10.1016/S0140-6736(19)33018-1.